OncoMatch/Clinical Trials/NCT05506332
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Is NCT05506332 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Venetoclax and 6-mercaptopurine for acute myeloid leukemia, in relapse.
Treatment: Venetoclax · 6-mercaptopurine — Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
WHO 0–2
Prior therapy
Must have received: intensive chemotherapy (ara-c, anthracycline) — relapsed or refractory after at least one cycle
Relapsed after or refractory to at least one cycle of intensive chemotherapy (combination of ara-c/anthracyclin)
Must have received: hypomethylating agent — relapsed or refractory after at least four cycles
or four cycles of HMA (hypomethylating agents)
Cannot have received: ABT-199 (venetoclax) and purine analogue (venetoclax)
Exception: Patient may be prior exposed but not refractory to venetoclax. In case of previous therapy with venetoclax inclusion is only possible after discussion with the PI.
ABT-199 (venetoclax) and PA-naïve. Patient may be prior exposed but not refractory to venetoclax. In case of previous therapy with venetoclax inclusion is only possible after discussion with the PI.
Cannot have received: antitumoral agent
Exception: Use within less than 5 times the half-life of the agent prior to the screening bone marrow examination
Use of any antitumoral agent within less than 5 times the half-life of the agent prior to the screening bone marrow examination
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify